Crypto Play Banks 176% Gains

Good Afternoon! 

Hey, everyone. It's Adam from Elite Trade Club. Here’s what moved the market today.

Fiscal Policy Winners (Sponsored)

How to Profit from the Current Administration’s Focus

Policy changes often spark market moves—and this latest investor report pinpoints 6 stocks aligned with current trends in Washington.

These companies could benefit from targeted spending, sector incentives, and regulatory tailwinds.

Previous picks from this strategy have surged triple digits. Now could be the time to act.

[Access the 6 Stock Picks Now]

(By submitting your email, you’ll also get a free Profit from the Pros membership, which highlights exclusive market updates and daily Strong Buy stocks. You can unsubscribe at any time. Privacy Policy)

Markets

Wall Street trimmed earlier gains on Thursday, as initial cheering over a U.S. court ruling against Trump’s trade tariffs faded, but a surge in Nvidia shares following its earnings report kept the market afloat.

Market-Moving News

Pharmaceuticals

Moderna Hit as Government Ends $766 Million Pandemic Vaccine Contract

Moderna (NASDAQ: MRNA) confirmed that the U.S. government has canceled a $766 million contract that supported the development of mRNA vaccines for pandemic influenza, including strains like H5N1. The termination also ends the government’s purchase rights tied to those doses.

Funding included a $590 million award issued earlier this year and an additional $176 million granted in 2024. The company stated that it will now explore alternative options for the late-stage development and production of its bird flu vaccine, mRNA-1018.

For investors, this decision introduces uncertainty around government-backed vaccine programs, which had been a key component of Moderna’s post-COVID growth story. The withdrawal may lead the company to rely more heavily on internal capital or private partnerships to move forward.

Even with the funding cut, Moderna shared early trial results showing its new vaccine triggered strong immunity in 98% of adults just three weeks after the second dose, and most people had no major side effects.

The government canceled its deal with Moderna just as concerns are growing about new disease threats like a fresh COVID variant (B.1.81) and bird flu cases spreading in several U.S. states. Moderna says it’s still focused on developing vaccines to prepare for future pandemics.

AI (Sponsored)

Wall Street May Be Sleeping on This AI Sleeper Pick

AI’s capabilities are growing rapidly—handling layered conversations, correcting itself, and adapting in real time.

This shift is opening up new frontiers for early investors.

A free report just revealed 5 high-potential stocks—including one under-the-radar name with breakout potential.

These tickers are positioned to ride the AI boom in its most advanced form yet.

[See the Top 5 AI Stocks – Free Access]

(By submitting your email, you’ll also get a free Profit from the Pros membership, which highlights exclusive market updates and daily Strong Buy stocks. You can unsubscribe at any time. Privacy Policy)

Retail

E.l.f. Beauty Makes Billion-Dollar Bet on Hailey Bieber’s Rhode

E.l.f. Beauty (NYSE: ELF) is expanding its presence in skincare with plans to acquire Hailey Bieber’s Rhode brand in a deal valued at up to $1 billion. The move puts E.l.f. on a path to compete more directly with skincare players.

Rhode was founded in 2022 and has grown quickly through a direct-to-consumer model. With just 10 products, it reportedly brought in over $200 million in sales last year. The acquisition includes cash, stock, and an earnout tied to performance.

Adding Rhode helps E.l.f. reach a different type of customer. Its core products sell around $6.50, while Rhode averages in the high $20s. That shift could help the company broaden its footprint in higher-margin categories while still leaning on its strengths in digital engagement and influencer reach.

For investors, the real opportunity is in scale. The beauty company has already proven it can build strong online brands; now it’s betting on replicating that success globally in skincare. Rhode’s rollout to retailers like Sephora is expected to begin later this year, which could drive more visibility and volume.

Timing remains a challenge, though. E.l.f. is taking on $600 million in debt to fund the deal while also dealing with China tariff exposure. But the long-term play is clear: tap into a premium market with staying power, and do it while the brand is still fresh and culturally relevant.

If E.l.f. can hold Rhode’s momentum and expand retail channels, this acquisition could shift the company’s growth trajectory meaningfully.

High-Rated Buys (Sponsored)

These 7 Stocks Could Move Fast

A new investor report reveals 7 stocks with breakout potential in the next 30 days.

These picks come from a proven ranking system that has more than doubled the S&P 500’s return—posting +24.2% average annual gains.

Only the top 5% of stocks even qualify, and these 7 are rated the highest right now.

The opportunity window is closing fast.

Download the full list—free.

Access the “7 Best Stocks for the Next 30 Days” now.

(By submitting your email, you’ll also get a free Profit from the Pros membership, which highlights exclusive market updates and daily Strong Buy stocks. You can unsubscribe at any time. Privacy Policy)

Aerospace

Boeing Set to Resume Jet Deliveries to China and Pushes Max Production Higher

Boeing (NYSE: BA) will resume airplane deliveries to China next month, marking the end of a pause that began during a trade standoff. With Chinese approvals reinstated, Boeing can now proceed with shipping new aircraft to one of its most critical markets.

First handovers are set for June, marking a major milestone in Boeing’s return to international growth. The company also plans to increase production of its best-selling 737 Max jets to 42 planes per month by mid-year, with a target of 47 planes per month by year-end.

With the restart of China deliveries, concerns around Boeing’s international exposure and balance sheet pressure could ease. The planned production hike signals improved supply chain stability and renewed confidence in demand. This progress may help rebuild trust following years of delays and setbacks tied to Max's safety incidents and certification hurdles.

Certification of Boeing’s Max 7 and Max 10 models is expected later this year, which would complete the Max family and expand Boeing’s ability to match varied airline needs. The return of China shipments may also lead to new orders down the line as carriers refresh fleets.

After a prolonged slump, Boeing is building momentum across production, deliveries, and global customer access.

Sharplink Gaming Inc [SBET] $80.59 (+176.40%)

Sharplink Gaming bounced back after a major correction on Wednesday. Investors are optimistic about its crypto bet, as it secured $425 million to buy ETH.

Streamline Health Solutions [STRM] $5.18 (+133.33%)

Streamline Health shares broke above the $5 mark for the first time this year amid MDaudit’s plans for an all-cash acquisition at a 138% premium, suggesting strong confidence in the health information tech firm.

Alzamend Neuro Inc [ALZN] $5.44 (+63.86%)

Alzamend Neuro rose after dosing the first patient in its Phase II trial for AL001, a lithium-based therapy showing potential for safer, more targeted treatment of brain disorders.

MicroCloud Hologram Inc [HOLO] $6.72 (-35.38%)

MicroCloud Hologram was one of the biggest losers today after rallying on Wednesday, as the retail-driven growth proved unsustainable.

Intellia Thera [NTLA] $7.45 (-22.88%)

Intellia Thera shares fell sharply after one patient in its trial had liver issues, causing concerns even though it didn’t need treatment and is now recovering.

Caleres Inc [CAL] $13.38 (-18.35%)

Caleres stock tumbled after missing Q1 earnings and revenue estimates, suspending its full-year outlook amid weak footwear sales and ongoing market uncertainty.

Limited Access (Sponsored)

New: 5 High-Upside Stock Picks—Free Report

A newly released report has identified 5 stocks with potential to double—or more—in the coming months.

The selection process filters for earnings strength, momentum, and industry tailwinds.

This is your chance to get the names before the crowd catches on.

[Download the Report Now]

*The results listed above are not (or may not be) representative of the performance of all selections made by Zacks Investment Research’s newsletter editors and may represent the partial close of a position.
*This free resource is being sent by Zacks. We look for investment resources and inform you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms of Service".

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.